Details of the Drug

General Information of Drug (ID: DMP9HHO)

Drug Name

TBI-223

Synonyms

TBI-223; UNII-B4RS1V5YSP; B4RS1V5YSP; 2071265-08-0; TBI 223; Carbamic acid, N-(((5S)-3-(3-fluoro-4-(2-oxa-6-azaspiro(3.3)hept-6-yl)phenyl)-2-oxo-5-oxazolidinyl)methyl)-, methyl ester; methyl N-[[(5S)-3-[3-fluoro-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]carbamate; CHEMBL5201490; SCHEMBL18408931; GTPL13029; AKOS040755770; AT39355; MS-25829; HY-139398; CS-0200359; methyl (S)-((3-(3-fluoro-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)carbamate; methyl N-[[(5S)-3-[3-fluoro-4-(6-oxa-2-azaspiro[3.3]heptan-2-yl)phenyl]-2-oxo-oxazolidin-5-yl]methyl]carbamate

Indication

Disease Entry	ICD 11	Status	REF
Tuberculosis	1B10-1B14	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C17H20FN3O5
Canonical SMILES: COC(=O)NCC1CN(C(=O)O1)C2=CC(=C(C=C2)N3CC4(C3)COC4)F
InChI: InChI=1S/C17H20FN3O5/c1-24-15(22)19-5-12-6-21(16(23)26-12)11-2-3-14(13(18)4-11)20-7-17(8-20)9-25-10-17/h2-4,12H,5-10H2,1H3,(H,19,22)/t12-/m0/s1
InChIKey: ZNBRXLSWXJKKLJ-LBPRGKRZSA-N

Cross-matching ID

PubChem CID: 126494519
TTD ID: D7PX3O

References

1	ClinicalTrials.gov (NCT03758612) A Phase 1, Partially-Blinded, Placebo-Controlled, Randomized, Single Ascending Dose (SAD) With a Food Effect Cohort Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adult Participants. U.S.National Institutes of Health.